Evolus (NASDAQ:EOLS) Shares Gap Up on Insider Buying Activity

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $9.87, but opened at $10.17. Evolus shares last traded at $10.38, with a volume of 256,876 shares trading hands.

Specifically, Director Albert G. White III purchased 20,000 shares of the business's stock in a transaction on Monday, June 9th. The stock was acquired at an average cost of $9.45 per share, for a total transaction of $189,000.00. Following the purchase, the director now directly owns 50,378 shares in the company, valued at $476,072.10. This trade represents a 65.84% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Analysts Set New Price Targets

EOLS has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Barclays upped their price target on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research started coverage on shares of Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus presently has a consensus rating of "Buy" and a consensus target price of $23.75.

Evolus Stock Performance

The stock has a fifty day simple moving average of $10.30 and a 200 day simple moving average of $11.84. The firm has a market capitalization of $660.23 million, a P/E ratio of -11.25 and a beta of 1.00. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently bought and sold shares of EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Evolus by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company's stock valued at $347,000 after purchasing an additional 1,094 shares in the last quarter. Rhumbline Advisers increased its stake in Evolus by 2.2% in the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock worth $885,000 after acquiring an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC raised its holdings in shares of Evolus by 18.2% during the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares in the last quarter. MetLife Investment Management LLC raised its stake in Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock valued at $378,000 after purchasing an additional 2,044 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in Evolus by 19.5% in the fourth quarter. Teacher Retirement System of Texas now owns 14,084 shares of the company's stock worth $155,000 after acquiring an additional 2,302 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.